touchRESPIRATORY caught up with Dr. Daniel Lachant (University of Rochester Medical Center, Rochester, NY, USA) around his analysis of the ADAPT Registry, investigating the transition from selexipag to oral treprostinil in patients with pulmonary arterial hypertension.
The abstract ‘Clinical Improvement in Pulmonary Arterial Hypertension (PAH) Patients Transitioning from Selexipag to Oral Treprostinil: Interim Results from the ADAPT Registry.’ (Abstract number: 608) was presented at ATS 2022, 13-18 May 2022.
Questions
- Since its approval, what has been the impact of treprostinil on the treatment paradigm for pulmonary arterial hypertension (PAH)? (0:36)
- What are the treatment goals in PAH and why has clinical improvement been a recent focus? (1:55)
- Could you tell us a little about the ADAPT registry and the aims of the current analysis? (2:56)
- What were the findings in patients who transitioned from selexipag to treprostinil? (3:58)
- What do you think are the reasons for this improvement after transitioning? (6:44)
Disclosures: Daniel Lachant discloses consulting for, receiving grant/ research support from, serving on advisory boards and speaker’s bureaus for United Therapeutics.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ATS meeting 2022.
